PMID- 33953419
OWN - NLM
STAT- MEDLINE
DCOM- 20220321
LR  - 20231213
IS  - 0386-300X (Print)
IS  - 0386-300X (Linking)
VI  - 75
IP  - 2
DP  - 2021 Apr
TI  - Efficacy and Safety of Ramucirumab/nab-paclitaxel for Previously Treated Advanced 
      Gastric Cancer in Community Hospitals.
PG  - 133-138
LID - 10.18926/AMO/61879 [doi]
AB  - As the nanoparticle albumin-bound paclitaxel (nab-PTX) is free of ethanol and 
      premedication, the duration of administration is shorter and patients can drive 
      themselves to and from the hospital. In the 2018 Japanese gastric cancer 
      treatment guidelines, ramucirumab (RAM) plus weekly nab-PTX is conditionally 
      recommended for previously treated patients with advanced gastric cancer. Here, 
      we retrospectively analysed the efficacy and safety of RAM+nab-PTX for such 
      patients in community hospitals. From January 2018 to December 2019, 43 patients 
      with metastatic and recurrent gastric cancer received RAM+nab-PTX treatment. Six 
      patients (13.9%) were older than 80 years and 9 patients (20.9%) showed ECOG-PS 
      2. Progression-free survival (PFS), overall survival (OS), overall response rate 
      (ORR), disease control rate (DCR), and adverse events (AEs) were reviewed 
      retrospectively. Median PFS was 114 days (95% confidence interval [CI]: 84-190) 
      and median OS was 297 days (95% CI: 180-398). ORR and DCR were 32.4% and 72.2%, 
      respectively. The incidence rates of >/=grade 3 neutropenia and febrile neutropenia 
      were 53.5% and 2.3%, respectively. No treatment-related deaths occurred. RAM plus 
      nab-PTX combination therapy demonstrated manageable toxicity even patients who 
      were elderly or had an ECOG-PS 2. This treatment is useful in community hospital 
      settings.
FAU - Hashida, Shinsuke
AU  - Hashida S
AD  - Department of Gastroenterological Surgery, Kagawa Prefectural Central Hospital.
FAU - Tanaka, Norimitsu
AU  - Tanaka N
AD  - Department of Gastroenterological Surgery, Kagawa Prefectural Central Hospital.
FAU - Takahashi, Yuta
AU  - Takahashi Y
AD  - Department of Gastroenterological Surgery, Kagawa Prefectural Central Hospital.
FAU - Onoda, Yuji
AU  - Onoda Y
AD  - Department of Gastroenterological Surgery, Kagawa Prefectural Central Hospital.
FAU - Colvin, Hugh Shunsuke
AU  - Colvin HS
AD  - Department of Gastroenterological Surgery, Kagawa Prefectural Central Hospital.
FAU - Ohashi, Ryuichiro
AU  - Ohashi R
AD  - Department of Gastroenterological Surgery, Kagawa Prefectural Central Hospital.
FAU - Okamoto, Kunio
AU  - Okamoto K
AD  - Department of Medical Oncology, Kagawa Prefectural Central Hospital.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Acta Med Okayama
JT  - Acta medica Okayama
JID - 0417611
RN  - 0 (Albumin-Bound Paclitaxel)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adenocarcinoma/*drug therapy
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Albumin-Bound Paclitaxel/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - Female
MH  - *Hospitals, Community
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Stomach Neoplasms/*drug therapy
MH  - Treatment Outcome
MH  - Ramucirumab
OTO - NOTNLM
OT  - gastric cancer
OT  - nab-paclitaxel
OT  - ramucirumab
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2021/05/07 06:00
MHDA- 2022/03/22 06:00
CRDT- 2021/05/06 06:58
PHST- 2021/05/06 06:58 [entrez]
PHST- 2021/05/07 06:00 [pubmed]
PHST- 2022/03/22 06:00 [medline]
AID - 10.18926/AMO/61879 [doi]
PST - ppublish
SO  - Acta Med Okayama. 2021 Apr;75(2):133-138. doi: 10.18926/AMO/61879.